



INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

Info: info@igbamedicines.org

IGBA welcomes Ana Gaunt as new Secretary General

For immediate release

Geneva, 24 March 2026 – The [International Generic and Biosimilar Medicines Association](#) (IGBA), has appointed Ana Gaunt as its new Secretary General with immediate effect, following the decision of Susana Almeida to step down from the role to pursue other opportunities.

Ana joins IGBA from a senior global programme leadership role in the pharmaceutical industry, bringing over twenty years of experience across generics, biosimilars, regulatory policy, and market access. Ana's career began at Medicines for Europe — then the European Generic Medicines Association — where she served as Health Economics Affairs Manager, representing the generics sector in EU-level policy discussions with the European Commission, national health ministries, regulatory agencies, and WHO-linked forums. That foundation in association advocacy was followed by senior roles at Sandoz and Novartis, spanning country and regional portfolio leadership and global programme management across Europe, Asia, and the Americas.

Statements:

“Ana joins the IGBA in an important moment of international policy shift. Her business acumen, deep knowledge of the pharmaceutical sector, and advocacy skills will help generics and biosimilars navigate the current environment. I am excited to work with Ana towards the achievement of IGBA’s goals of contributing to enhanced patient access to safe, effective, cost-effective and quality-assured medicines.”

— [Jim Keon](#), Chair, IGBA

“IGBA thanks Susana for her service during these past 2 years, which helped strengthen IGBA’s position as a key global health stakeholder. We recall important milestones, such as the release of the [IGBA IP and Competition Report](#), the [Single Global Development report](#), and sustained relationships with key global stakeholders, including UN Agencies.”

— [Mariano Genovesi](#), Vice-Chair, IGBA

“I am glad to be joining IGBA at a time when the issues this sector works on — access, regulatory harmonisation, biosimilar confidence, supply resilience — are genuinely important to health systems everywhere. I look forward to working with the membership and the Secretariat to advance these priorities, and to making sure IGBA's voice in international policy debates reflects the full breadth of what this industry contributes.”

— [Ana Gaunt](#), Secretary General, IGBA

Strategic Priorities

Under Ana's leadership, IGBA will continue its work on regulatory convergence across jurisdictions, biosimilar policy and uptake, the contribution of generic medicines to sustainable health financing, supply chain resilience, balanced IP systems, and engagement with multilateral institutions including the UN Agencies and Regulatory harmonization organisations.

About IGBA: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org